Fine Radar
The News Hub

Distributor limiting allocation of low dose Wegovy

Distributor Novo Nordisk has decided to limit low doses of obesity medication Wegovy in the U.S. as demand outpaces supply.

Novo Nordisk, a global healthcare and pharmaceutical company based in Denmark, is limiting the supply of Wegovy to conserve doses for patients already using the drug, the company said Thursday.

The company is still supplying “limited quantities” of 0.25, 0.5 and 1 mg doses to wholesalers for distribution to different retail pharmacies.

Wegovy was approved as a weight management treatment medication by the Food and Drug Administration in 2021.

The medication belongs to a class of drugs called GLP-1 agonists that have caught on in the weight loss industry, according to CBS News. Endorsements by celebrities on social media have only further fueled shortages nationwide.

“Today we are serving hundreds of thousands of U.S. patients with Wegovy,” the company said in a statement. “However, trends indicate that demand for Wegovy in the U.S. will exceed our current supply capacity.”

Copyright 2023 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

For more latest Health News Click Here 

Read original article here

Denial of responsibility! FineRadar is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
Leave A Reply

Your email address will not be published.